Deepverge PLC represents a strong commitment to innovation, sustainability, and technological advancements. The company is focused on leveraging cutting-edge technologies to address critical challenges in industries such as healthcare, environmental monitoring, and consumer safety. With a forward-thinking corporate philosophy, Deepverge aims to revolutionize these sectors by providing smart solutions powered by AI, big data analytics, and IoT. By continuously pushing boundaries and striving for excellence, Deepverge PLC aims to create long-term value for its stakeholders and contribute to a more sustainable and connected world.

Deepverge PLC is primarily present in the United Kingdom.

Deepverge PLC, a leading company in the field of artificial intelligence and digital pathology, has achieved several significant milestones. One noteworthy accomplishment is the development and implementation of AI-powered solutions for advanced real-time water and air monitoring. Through their Microtox technology, Deepverge PLC has successfully provided accurate and timely data analysis, enabling effective environmental management. Additionally, the company has established strategic partnerships with multinational corporations and academic institutions, fostering collaboration and driving innovation. Furthermore, Deepverge PLC has demonstrated impressive growth, expanding its market presence and establishing a strong global customer base. Overall, Deepverge PLC continues to make substantial strides in revolutionizing environmental monitoring and leveraging AI technology for sustainable solutions.

Deepverge PLC is a leading technology company specializing in AI-driven digital pathology and skincare diagnostics. Founded in 2010, Deepverge has consistently evolved its expertise in artificial intelligence, machine learning, and microanalytics. The company's cutting-edge solutions provide innovative insights into disease detection, infection control, and environmental monitoring. Deepverge PLC's advanced technologies are utilized across various industries, including pharmaceuticals, healthcare, and consumer products. With a commitment to revolutionizing diagnostics and improving overall human health, Deepverge PLC continues to pioneer groundbreaking advancements in the field of digital pathology.

The main competitors of Deepverge PLC in the market are companies such as IBM, Microsoft, and Google.

Deepverge PLC is primarily active in the industries of digital pathology and healthcare. By leveraging sophisticated Artificial Intelligence and Machine Learning technologies, Deepverge PLC provides innovative solutions for medical diagnostics, environmental testing, and water monitoring. With a strong focus on improving global health, Deepverge PLC's cutting-edge technologies enable rapid, accurate, and cost-effective analysis of samples, empowering healthcare professionals and scientists with valuable insights. As a leader in its field, Deepverge PLC continues to drive advancements in digital pathology and contribute to the progress of medical research and diagnostics.

The business model of Deepverge PLC revolves around providing innovative digital solutions for industries such as healthcare, personal care, and environmental monitoring. Deepverge PLC combines artificial intelligence, bioinformatics, and deep learning technologies to offer advanced data analytics and real-time insights. The company focuses on developing cutting-edge technologies that enable efficient monitoring, analysis, and management of data to drive actionable results. Deepverge PLC's business model aims to provide valuable solutions that enhance operational efficiency, regulatory compliance, and overall performance in various sectors.

P/E santykio šiuo metu Deepverge apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas Deepverge.

AlleAktien kokybės įvertis Deepverge yra 3/10.

Pajamos šiuo metu negali būti apskaičiuotos Deepverge.

Pelnas šiuo metu negali būti apskaičiuotas Deepverge.

Deepverge PLC is a publicly traded company specializing in the development of artificial intelligence (AI) products and technologies. Its business model revolves around developing and selling a wide range of products and services across various markets. One of Deepverge's key divisions is its biowarfare division, which focuses on developing technologies and products for analyzing samples in the field of biomedicine. The company has developed a powerful "AI as a Service" offering that utilizes AI-based algorithms and advanced image processing technologies to swiftly and accurately analyze complex biological samples. Deepverge also has a subsidiary called Paraytec Ltd., which specializes in the development of miniature UV spectroscopy devices. Paraytec has created a miniature spectroscopy device that optimizes separation technologies in the production of biopharmaceuticals and monitors industrial processes. Another important division of Deepverge is its water analytics division, which concentrates on developing solutions for monitoring water quality. The company has developed a water monitoring platform called Microtox®️, which relies on AI-based technologies to rapidly and accurately identify contaminants and pollutants in water samples. Deepverge has also developed a robust portfolio of products and services for leveraging AI and machine learning in the pharmaceutical industry. The company has created a software called SYMPHONY that enables rapid and effective analysis of pharmaceutical data and samples. The software utilizes machine learning and AI to allow for better prediction of drug efficacy and toxicity, resulting in cost-effective and personalized drug development. In addition to these divisions, Deepverge also offers a range of services in the field of AI and machine learning, including the development of tailor-made AI solutions for businesses and organizations. The company's technology stacks enable companies to integrate the latest AI-based technologies and methods into their business processes to enhance efficiency and profitability. Overall, Deepverge has developed a diverse portfolio of products and services offered across various markets. The company has established itself as a leader in the field of AI and machine learning and is well-positioned to experience strong growth in the coming years by providing the latest technologies and solutions to tackle future challenges.

Deepverge moka dividendą 0 GBP, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Deepverge arba įmonė dividendų nemoka.

Deepverge ISIN yra GB00BMGWZY29.

Deepverge WKN yra A2QEPJ.

Deepverge akcijų simbolis yra DVRG.L.

Per paskutinius 12 mėnesių Deepverge išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Deepverge tikėtina išmokės dividendus, kurie sudarys 0 GBP.

Deepverge šiuo metu yra dydžio dividendų grąža.

Deepverge moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Deepverge per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 GBP. Tai atitinka 0 % dividendų grąžos procentą.

Deepverge priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Deepverge dividendą nuo 2024-09-09, kurio dydis yra 0 GBP, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-09.

Paskutinės dividendų išmokėjimas įvyko 2024-09-09.

2023 metais Deepverge išmokėjo 0 GBP dividendų.

Deepverge dividendai yra mokami GBP.